LearnGlossaryMarketStocksSuperinvestorsSign in

IRD

Opus Genetics, Inc.

Healthcare · $410M market cap

Verdict

We can't put a fair value on IRD right now. It looks like a preferred share, note or other security rather than ordinary common stock. The figures we receive belong to the parent company, so they can't value this security.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-65.6% a year✗
Sales growth-36.0% a year✗
Free cash flow growth—?
Return on invested capital-24.4%✗

Follow IRD

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 3, 2026: no open-market purchases, 1 sale worth $127K and 3 other filings (stock awards, tax withholding and similar). Why purchases matter

Sales

Gagnon Robert E.

Chief Financial Officer · 2026-09-03

Sold

$127K

Other filings

Magrath George

Chief Executive Officer · 2026-09-09

Tax withholding

$451K

Magrath George

Chief Executive Officer · 2026-09-09

Option exercise

$451K

Gallagher Cam

director · 2026-09-08

Option exercise

$902K

About Opus Genetics, Inc.

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation)…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works